Tags

Type your tag names separated by a space and hit enter

Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
Euro Surveill. 2016; 21(7):pii=30139.ES

Abstract

Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a multicentre case-control study in eight European countries to measure 2014/15 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed all or a systematic sample of ILI patients. We compared the odds of vaccination of ILI influenza positive patients to negative patients. We calculated adjusted VE by influenza type/subtype, and age group. Among 6,579 ILI patients included, 1,828 were A(H3N2), 539 A(H1N1)pdm09 and 1,038 B. VE against A(H3N2) was 14.4% (95% confidence interval (CI): -6.3 to 31.0) overall, 20.7% (95%CI: -22.3 to 48.5), 10.9% (95%CI -30.8 to 39.3) and 15.8% (95% CI: -20.2 to 41.0) among those aged 0-14, 15-59 and ≥60 years, respectively. VE against A(H1N1)pdm09 was 54.2% (95%CI: 31.2 to 69.6) overall, 73.1% (95%CI: 39.6 to 88.1), 59.7% (95%CI: 10.9 to 81.8), and 22.4% (95%CI: -44.4 to 58.4) among those aged 0-14, 15-59 and ≥60 years respectively. VE against B was 48.0% (95%CI: 28.9 to 61.9) overall, 62.1% (95%CI: 14.9 to 83.1), 41.4% (95%CI: 6.2 to 63.4) and 50.4% (95%CI: 14.6 to 71.2) among those aged 0-14, 15-59 and ≥60 years respectively. VE against A(H1N1)pdm09 and B was moderate. The low VE against A(H3N2) is consistent with the reported mismatch between circulating and vaccine strains.

Authors+Show Affiliations

Epidemiology Department, EpiConcept, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26924024

Citation

Valenciano, Marta, et al. "Vaccine Effectiveness in Preventing Laboratory-confirmed Influenza in Primary Care Patients in a Season of Co-circulation of Influenza A(H1N1)pdm09, B and Drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 21, no. 7, 2016, pp. pii=30139.
Valenciano M, Kissling E, Reuss A, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016;21(7):pii=30139.
Valenciano, M., Kissling, E., Reuss, A., Rizzo, C., Gherasim, A., Horváth, J. K., Domegan, L., Pitigoi, D., Machado, A., Paradowska-Stankiewicz, I. A., Bella, A., Larrauri, A., Ferenczi, A., Lazar, M., Pechirra, P., Korczyńska, M. R., Pozo, F., & Moren, A. (2016). Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 21(7), pii=30139. https://doi.org/10.2807/1560-7917.ES.2016.21.7.30139
Valenciano M, et al. Vaccine Effectiveness in Preventing Laboratory-confirmed Influenza in Primary Care Patients in a Season of Co-circulation of Influenza A(H1N1)pdm09, B and Drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill. 2016;21(7):pii=30139. PubMed PMID: 26924024.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. AU - Valenciano,Marta, AU - Kissling,Esther, AU - Reuss,Annicka, AU - Rizzo,Caterina, AU - Gherasim,Alin, AU - Horváth,Judit Krisztina, AU - Domegan,Lisa, AU - Pitigoi,Daniela, AU - Machado,Ausenda, AU - Paradowska-Stankiewicz,Iwona Anna, AU - Bella,Antonino, AU - Larrauri,Amparo, AU - Ferenczi,Annamária, AU - ,, AU - Lazar,Mihaela, AU - Pechirra,Pedro, AU - Korczyńska,Monika Roberta, AU - Pozo,Francisco, AU - Moren,Alain, AU - ,, PY - 2015/10/12/received PY - 2015/11/25/accepted PY - 2016/3/1/entrez PY - 2016/3/1/pubmed PY - 2016/8/16/medline KW - influenza KW - influenza vaccine effectiveness KW - multicentre case-control study KW - vaccines and immunisation SP - pii=30139 EP - pii=30139 JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill. VL - 21 IS - 7 N2 - Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a multicentre case-control study in eight European countries to measure 2014/15 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed all or a systematic sample of ILI patients. We compared the odds of vaccination of ILI influenza positive patients to negative patients. We calculated adjusted VE by influenza type/subtype, and age group. Among 6,579 ILI patients included, 1,828 were A(H3N2), 539 A(H1N1)pdm09 and 1,038 B. VE against A(H3N2) was 14.4% (95% confidence interval (CI): -6.3 to 31.0) overall, 20.7% (95%CI: -22.3 to 48.5), 10.9% (95%CI -30.8 to 39.3) and 15.8% (95% CI: -20.2 to 41.0) among those aged 0-14, 15-59 and ≥60 years, respectively. VE against A(H1N1)pdm09 was 54.2% (95%CI: 31.2 to 69.6) overall, 73.1% (95%CI: 39.6 to 88.1), 59.7% (95%CI: 10.9 to 81.8), and 22.4% (95%CI: -44.4 to 58.4) among those aged 0-14, 15-59 and ≥60 years respectively. VE against B was 48.0% (95%CI: 28.9 to 61.9) overall, 62.1% (95%CI: 14.9 to 83.1), 41.4% (95%CI: 6.2 to 63.4) and 50.4% (95%CI: 14.6 to 71.2) among those aged 0-14, 15-59 and ≥60 years respectively. VE against A(H1N1)pdm09 and B was moderate. The low VE against A(H3N2) is consistent with the reported mismatch between circulating and vaccine strains. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/26924024/Vaccine_effectiveness_in_preventing_laboratory_confirmed_influenza_in_primary_care_patients_in_a_season_of_co_circulation_of_influenza_A_H1N1_pdm09_B_and_drifted_A_H3N2__I_MOVE_Multicentre_Case_Control_Study_Europe_2014/15_ L2 - http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21385 DB - PRIME DP - Unbound Medicine ER -